Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
February 21, 2024 08:00 ET
|
Annexon Biosciences
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2024 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
January 07, 2024 20:00 ET
|
Annexon Biosciences
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in...
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
December 20, 2023 17:27 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
December 20, 2023 17:10 ET
|
Annexon Biosciences
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled...
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
December 20, 2023 17:08 ET
|
Annexon Biosciences
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
November 13, 2023 06:30 ET
|
Annexon Biosciences
Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ...